Search

A recent study conducted at the University of Lisbon focused on patient-reported outcome measures (PROMs) in type 1 diabetes outpatient care. The research aimed to assess how individuals perceive the disease and its impact on quality of life, alongside metabolic control. The study included 56 participants and found that psychological adjustment to diabetes correlated with well-being and depression symptoms, highlighting the importance of addressing mental health in diabetes management to improve quality of life. [Extracted from the article]

The article discusses a clinical trial, NCT06642623, focusing on the sodium-glucose cotransporter-2 (SGLT2) inhibitor, enavogliflozin, and its impact on cardiovascular and renal outcomes in patients with type 2 diabetes. The trial aims to determine if enavogliflozin is non-inferior to other SGLT2 inhibitors in terms of cardiorenal outcomes. The study involves 2,862 participants randomly assigned to receive enavogliflozin or other SGLT2 inhibitors, such as dapagliflozin or empagliflozin, with proven cardiorenal benefits. The primary endpoint is the time to the first occurrence of major adverse cardiovascular and renal events, aiming to prevent vascular complications in this patient population. [Extracted from the article]

The article discusses a clinical trial, NCT06643936, launched by Rush University Medical Center to address racial disparities in type 2 diabetes control among African American and Latinx patients. The trial aims to improve glycemic control through a multidisciplinary team approach, remote monitoring, medication adherence support, and culturally tailored education. The study will involve 150 participants and is set to be completed by November 30, 2025. The intervention group is expected to achieve a change in A1c of 0.5 in at least 30% of participants in 6 months, surpassing the control group receiving standard care. [Extracted from the article]

A clinical trial, NCT06643611, aims to improve the health of uninsured minority patients with type 2 diabetes by integrating continuous glucose monitors and pharmacist medication management. The study focuses on Black and Hispanic populations with poor glycemic control on basal insulin. The trial will assess outcomes such as changes in Hemoglobin A1c levels, health-related quality of life, treatment satisfaction, medication adherence, and glucose management indicators. The intervention arm will receive continuous glucose monitors in addition to usual care, while the control arm will receive routine physician visits. [Extracted from the article]

The article discusses a pilot clinical trial, NUTRI-Beta Study, aimed at children with a new diagnosis of stage 3 type 1 diabetes. The study investigates the effects of weekly distribution of healthy foods and intensive nutrition counseling as complementary therapies to standard insulin therapy. The goal is to prolong the honeymoon phase, promote beta cell function survival, and reduce progression to stage 4 type 1 diabetes. The study design includes a 12-week intervention with a focus on nutrition quality, glycemic metrics, and insulin requirements. [Extracted from the article]

A recent study conducted at Yale University focused on the effects of Teplizumab, a drug used to delay the progression of type 1 diabetes in at-risk patients. The research found that after 5 years, 36% of participants remained free of clinical diabetes, suggesting operational tolerance. The study analyzed changes in the antigen-specific repertoire of T cells in response to Teplizumab treatment, indicating a promotion of operational tolerance and prevention of expansion of autoreactive T cells. [Extracted from the article]

Researchers from the Diabetes Research Institute in Milan, Italy, have conducted studies in the field of regenerative medicine, specifically focusing on cell therapy for type 1 diabetes. The research highlights the advancements in beta cell replacement, stemming from islet transplantation experiences and ongoing clinical trials using beta cells derived from stem cells. The study emphasizes the challenges of protecting beta cells from rejection due to immunological barriers, while also showcasing the potential of generating functional beta cells from pluripotent stem cells. This research contributes to the rapid progress in the field of beta cell replacement, building on the knowledge gained from islet transplantation experiences. [Extracted from the article]

The article discusses the identification of subphenotypes of type 2 diabetes mellitus (T2DM) and their implications for treatment and risk of complications. Through data pooling and clustering, four subphenotypes were identified: severe insulin-deficient diabetes, severe insulin-resistant diabetes, mild obesity-related diabetes, and mild age-related diabetes. The study highlights the heterogeneity in newly diagnosed T2DM and the potential for tailored treatment strategies based on subphenotypes, despite limitations in routine clinical settings. [Extracted from the article]

The article discusses a clinical trial, NCT06644651, focusing on inflammation in the arteries of the heart in individuals with type 2 diabetes. The study uses a heart CT scan to measure inflammation by examining the fat tissue surrounding the heart arteries. The research aims to determine if inflammation in the fat tissue can predict plaque characteristics, the development of cardiovascular events, and major adverse cardiovascular events over a 7-year follow-up period. The study involves cardiovascular asymptomatic participants with type 2 diabetes and examines various outcomes related to inflammation, plaque features, and cardiovascular events. [Extracted from the article]

A recent study conducted at Benha University focused on evaluating vascular changes in the foveal avascular zone in pediatric patients with type 1 diabetes using optical coherence tomography angiography (OCTA). The study included 48 patients divided into two groups, with results showing wider foveal avascular zones in type 1 diabetic cases compared to healthy controls, along with differences in foveal thickness. The research suggests that OCTA could potentially identify microvascular changes in patients before the onset of clinically evident diabetes retinopathy, highlighting the need for further prospective studies in this area. For more information, the full article can be accessed through the Journal of the Egyptian Ophthalmological Society. [Extracted from the article]

A recent study conducted at the Steno Diabetes Center in Copenhagen, Denmark, explored the challenges posed by open-source automated insulin delivery systems for individuals with Type 1 Diabetes and healthcare professionals. The research highlighted three main challenges: lack of exchange of experiences, unclear ethical responsibility, and unresolved individual and mutual expectations. The study emphasized the need for improved knowledge about these systems, an open-minded approach from healthcare professionals, and a focus on psychosocial aspects in interactions with service-users. This peer-reviewed research provides valuable insights into enhancing the interaction between individuals with Type 1 Diabetes and healthcare professionals. [Extracted from the article]